Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

iwMyeloma 2023

17–19 March 2023 | Madrid, Spain

VJHemOnc is pleased to be the official media partner for the 16th International Workshop on Myeloma (iwMyeloma), which was held in Madrid, Spain on 17-19 March 2023.

The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in multiple myeloma with the aim to optimize clinical care.

Click here to view the roundtable discussion for each of the sessions.

Genomics 2023 Overcoming treatment resistance Novel targets part 1 Future of myeloma therapy Novel targets part 2 Curing myeloma and how to achieve it T-cell engagers

Session 1: Genomics 2023

Gareth Morgan

Biology of HR

Gareth Morgan NYU Langone Health, New York City, NY, United States

Leif Bergsagel

The genomics and definition of SMM

Leif Bergsagel Mayo Clinic, Phoenix, AZ, United States

Francesco Maura

Time of origin and evolutionary trajectories to MM

Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States

Jill Corre

Molecular definitions of high-risk MM and their utility for trial entry

Jill Corre The Cancer University Institute of Toulouse Oncopole, Toulouse, France

Niels Weinhold

Clonal substructure and drivers of MM relapse

Niels Weinhold Heidelberg University, Heidelberg, Germany

Session 2: Overcoming treatment resistance

Irene Ghobrial

Resistance mechanisms mediated via the microenvironment

Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States

Session 3: Novel targets part 1

Marta Chesi

Using the Vk*MYC mouse model to understand early stages of myeloma

Marta Chesi Mayo Clinic, Phoenix, AZ, United States

José Ángel Martínez-Climent

Pre-clinical MM models for predicting clinical immunotherapy outcomes

José Ángel Martínez-Climent University of Navarra, Navarra, Spain

Felipe Prósper

Utility of epigenetic analysis of MM plasma cells

Felipe Prósper University of Navarra, Navarra, Spain

Maria-Victoria Mateos

Novel risk scores and endpoints for trials in SMM trials

Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain

Session 4: Future of myeloma therapy

Claudia Stege

The clinical utility of frailty in clinical trial designs

Claudia Stege Amsterdam UMC, Amsterdam, Netherlands

Brian Walker

Translational studies for MM trials in the USA

Brian Walker University of Arkansas for Medical Sciences, Little Rock, AR, United States

Session 5: Novel targets part 2

Elena Zamagni

Utilising imaging modalities as endpoints in clinical trials

Elena Zamagni University of Bologna, Bologna, Italy

Enrique Ocio

Other therapeutic vulnerabilities (Modakafusp, PDCs, BCL2 inhibitors)

Enrique Ocio Marqués de Valdecilla University Hospital, Santander, Spain

Carlos Fernández De Larrea

Innovative CAR-T designs and targets

Carlos Fernández De Larrea Hospital Clínic de Barcelona, Barcelona, Spain

Session 6: Curing myeloma and how to achieve it

Pieter Sonneveld

European perspective

Pieter Sonneveld Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

Sagar Lonial

US perspective

Sagar Lonial Emory Winship Cancer Institute, Atlanta, GA, United States

Session 7: T-cell engagers

Maria-Victoria Mateos

T-Cell Engagers

Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain

Suzanne Trudel

Teclistamab

Suzanne Trudel Princess Margaret Cancer Centre, Toronto, Canada

Yi Lin

Ide-cel

Yi Lin Mayo Clinic, Rochester, MN, United States

Adam Cohen

Cilta-cel

Adam Cohen University of Pennsylvania, Philadelphia, PA, United States

Paula Rodríguez-Otero

Talquetamab

Paula Rodríguez-Otero University of Navarra, Navarra, Spain

Eric Smith

GPRC5D CAR T-cells

Eric Smith Dana-Farber Cancer Institute, Boston, MA, United States

iwMyeloma 2023 was supported by:

For the latest updates in multiple myeloma, visit The Myeloma Channel